You are here

Our science / Clinical Trials / Find a Trial / NCT00189332

Use of 852A in Metastatic Cutaneous Melanoma.

Back to Search Print Save as PDF Bookmark Trial

NCT00189332

Last updated on August 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Hôpital Hotel Dieu, 1, Pace de l' Hôpital,
Lyon, , France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma, Unresectable Metatstatic Cutaneous Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Advanced melanoma not responding to 1st line chemotherapy

- Histological evidence of melanoma

- Measurable disease according to RECIST criteria

- ECOG performance status less than or equal to 2

- Life expectancy 6 months or more

- Normal organ and bone marrow function as defined by hematological and serum chemistry
limits

- Adequate contraception for females of childbearing potential

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Stage IV disease which has previously progressed during interferon treatment.

- Restriction of some therapies/medications for a certain timeframe prior to enrollment
and during the study including: investigational drugs, high dose corticosteroids,
immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong
QT interval and/or induce Torsades De Pointes

- History of uncontrolled seizure disorders

- Uncontrolled coagulation disorders.

- History or evidence of myocardial ischemia, congestive heart failure or arrythmias
requiring treatment in the past 6 months

- History of uncontrolled intercurrent or chronic illness

- Concurrent malignancies.

- Brain metastases.

- HIV positive.

- Prolonged QTc interval

- Uncontrolled intercurrent or chronic illnesses.

- Pregnant or lactating women

NCT00189332
Pfizer
Completed
Use of 852A in Metastatic Cutaneous Melanoma.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
NCT02573259
All Genders
18+
Years
Multiple Sites
Non-Hodgkin Lymphoma, Follicular Lymphoma, Large B-Cell Lymphoma, Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Squamous Cell of Head and Neck Carcinoma, Malignant Melanoma
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307267
All Genders
18+
Years
Multiple Sites
Melanoma, Unresectable Metatstatic Cutaneous Melanoma
Use of 852A in Metastatic Cutaneous Melanoma.
NCT00189332
All Genders
18+
Years
Multiple Sites
Liver Neoplasms, Unresectable Hepatocellular Carcinoma
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
NCT00247676
All Genders
18+
Years
Multiple Sites
Use of 852A in Metastatic Cutaneous Melanoma.
Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Melanoma
  • Unresectable Metatstatic Cutaneous Melanoma
Drug: 852A
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
August 2006
August 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Advanced melanoma not responding to 1st line chemotherapy
  • Histological evidence of melanoma
  • Measurable disease according to RECIST criteria
  • ECOG performance status less than or equal to 2
  • Life expectancy 6 months or more
  • Normal organ and bone marrow function as defined by hematological and serum chemistry limits
  • Adequate contraception for females of childbearing potential

Exclusion Criteria:

  • Stage IV disease which has previously progressed during interferon treatment.
  • Restriction of some therapies/medications for a certain timeframe prior to enrollment and during the study including: investigational drugs, high dose corticosteroids, immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong QT interval and/or induce Torsades De Pointes
  • History of uncontrolled seizure disorders
  • Uncontrolled coagulation disorders.
  • History or evidence of myocardial ischemia, congestive heart failure or arrythmias requiring treatment in the past 6 months
  • History of uncontrolled intercurrent or chronic illness
  • Concurrent malignancies.
  • Brain metastases.
  • HIV positive.
  • Prolonged QTc interval
  • Uncontrolled intercurrent or chronic illnesses.
  • Pregnant or lactating women
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France,   Germany,   Switzerland
 
 
NCT00189332
1527-852A
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Not Provided
Pfizer
October 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now